![]() |
|
|
Vol. 300, Issue 3, 1046-1052, March 2002
Oklahoma Foundation for Digestive Research Basic Science Laboratories, Veterans Affairs Medical Center, Oklahoma City, Oklahoma (K.V., B.G.-V.M.); and TAP Pharmaceutical Products Inc., Lake Forest, Illinois (D.M.S.-M.)
| |
Abstract |
|---|
|
|
|---|
Pathways controlling gastrointestinal function involve the activation
of neurokinin NK1 receptors by substance P (SP) under normal and pathological conditions. Our aim was to pharmacologically characterize the effect of a nonpeptide NK1 receptor
antagonist TAK-637
[(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g] [1,7]naphthyridine-6,13-dione] and determine key mechanisms of TAK-637 action in the gastrointestinal tract. Experiments were performed using intestinal preparations isolated from the guinea pig.
The selective agonists of NK1 receptors,
[Sar9,Met(O2)11]-SP and GR 73632 [H2N-(CH2)4-CO-Phe-Phe-Pro-NMe-Leu-Met-NH2], induced contractions in colonic longitudinal muscle pretreated with
atropine. TAK-637 (1-100 nM) caused a rightward shift of the
concentration-response curves showing nanomolar affinity against [Sar9,Met(O2)11]-SP
(Kb = 4.7 nM) and GR 73632 (Kb = 1.8 nM). This antagonist effect
remained unchanged by tetrodotoxin. Furthermore, neither the
contractions of colonic circular muscle induced by selective activation
of NK2 receptors by GR 64349 (Lys-Asp-Ser-Phe-Val-Gly-R-
-lactam-Leu-Met-NH2) nor the
responses of taenia coli induced by the selective
NK3 receptor agonist senktide were affected by TAK-637 (100 nM). Studies of electrically induced neurogenic contractions showed
that TAK-637 had no effect on cholinergic responses to single-pulse
(0.5 ms) stimulation or stimulation with increasing frequency (1-16
Hz, 0.5 ms, 5-s train duration). In contrast, TAK-637 significantly reduced nonadrenergic, noncholinergic contractions of colonic longitudinal muscle evoked at frequencies of 8 to 16 Hz and prevented the development of capsaicin-induced contractions in isolated segments
of terminal ileum. Our results indicate that TAK-637 is a selective
antagonist of smooth muscle NK1 receptors that activate
intestinal muscle contraction. Additionally TAK-637 inhibits neuronal
NK1 receptors involved in the "local" motor response to
stimulation of capsaicin-sensitive primary afferents.
| |
Introduction |
|---|
|
|
|---|
Substance
P (SP), neurokinin A, and neurokinin B are a family of small,
biologically active peptides, known as tachykinins, which stimulate a
wide range of effects through activation of three distinct receptor
types designated NK1, NK2,
and NK3, respectively. Tachykinins mediate a
variety of central and peripheral physiological responses regulating
the function of the cardiovascular, respiratory, gastrointestinal,
genitourinary, and immune systems (Holzer and Holzer-Petsche, 1997a
,b
;
Quartara and Maggi, 1998
). Tachykinins also have pathophysiological
effects as proinflammatory mediators and neurotransmitters of
peripheral and central pathways responsible for the perception of pain
and neurogenic inflammation (Cuello et al., 1993
).
In the gastrointestinal tract, SP is expressed in enteric neurons and
extrinsic afferent fibers (Costa et al., 1985
) and acts as an
endogenous ligand binding preferentially to NK1
receptors in neurons, endothelial cells and endocrine cells within the
gastrointestinal epithelium, fibroblasts, smooth muscle, inflammatory,
and immune cells. The motor action of tachykinins is associated with
activation of NK1 receptors, causing contractions
of intestinal muscles (Holzer and Lembeck, 1980
; Maggi et al., 1994
) or
epithelial secretion (Perdue et al., 1987
; Brown et al., 1992
; Cooke et
al., 1997
). SP is implicated in the neurally coordinated control of
motility and mucosal secretion (Greenwood et al., 1990
), acting as a
neurotransmitter often coreleased with acetylcholine (Bartho and
Holzer, 1985
; Costa et al., 1996
). Functional studies have indicated
that NK1, NK2, and
NK3 tachykinin receptor types in the intestine
are involved in peristaltic reflexes. In general,
NK3 receptors are localized on neurons, whereas
NK1 and NK2 receptors are
found on muscle cells (Maggi et al., 1993b
; Maggi, 1995
).
However, in the guinea pig ileum, NK1 receptors
have been located on inhibitory (Portbury et al., 1996
) and excitatory
(Southwell et al., 1998
) motor neurons and are implicated in
activation of enteric reflex circuits activated by villous movement
(Southwell et al., 1998
). In addition, SP is coexpressed with
calcitonin gene-related peptide in the peripheral endings of extrinsic
primary afferent fibers. Studies have also shown that SP is
functionally involved in the perception of pain (Bueno et al., 1997
)
and in enterotoxin-induced reflex secretion in the small intestine
(Sjoqvist et al., 1993
).
Compromised motility in various gastrointestinal disorders is
linked to abnormal tachykinin-mediated regulation of the activity of
both nerves and muscles involved in enteric and peripheral reflexes.
The discovery of tachykinin antagonists, which distinguish between the
NK1, NK2, or
NK3 tachykinin receptors, presents a more
selective therapeutic approach to the normalization of intestinal motility and pain perception. A novel nonpeptide
NK1 receptor antagonist TAK-637
[(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g] [1,7]naphthyridine-6,13-dione] has recently been found to reduce sensory transmission from the bladder acting as an inhibitor of spinal
viscero-visceral reflexes in guinea pigs (Doi et al., 2000
; Kamo et
al., 2000
) and to reduce stress-related propulsive activity of the
colon (Okano et al., 2001
). The aim of the present study was to
investigate the peripheral action of TAK-637 on
NK1 receptor-mediated effects in the
gastrointestinal tract. It is well known that NK1 receptors show interspecies heterogeneity; however, there is a close
similarity between human and guinea pig receptors (Takeda et al., 1991
;
Gorbulev et al., 1992
) whereas rat NK1 receptors are quite different (Yokota et al., 1989
). Thus, we studied the pharmacology of TAK-637 in vitro using intestinal preparations isolated
from the guinea pig. Our study provided functional evidence that
TAK-637 is a selective antagonist of peripheral
NK1 receptors.
| |
Materials and Methods |
|---|
|
|
|---|
Experimental Animals. Male Dunkin-Hartley guinea pigs (350-400 g body weight) purchased from Harlan Sprague-Dawley, Inc. (Indianapolis, IN) were used in the experiments. The animals were housed two per cage under environmentally controlled conditions (21°C, 12-h light/dark cycle) with free access to food and water. All animals were allowed to acclimatize to the environment in the animal facility for at least 1 week prior to experiments. The animals were killed by sectioning the carotid arteries under isoflurane anesthesia, and intestinal tissue was harvested immediately. A total of 35 guinea pigs were used in the study. The experimental protocol was approved by the Oklahoma City Veterans Affairs Medical Center Animal Care Committee.
Isometric Contractile Activity in Isolated Intestinal Preparations. Segments of the mid portion of the colon, the ileum (20 cm proximal to the ileocecal junction), or the terminal ileum (5-15 cm proximal to the ileocecal junction), as well as the taenia coli, were isolated and placed in ice-cold Krebs-bicarbonate solution that was continuously aerated with 95% O2 and 5% CO2. Muscle strips (10-12-mm long) containing both muscle layers were dissected from the mucosa-submucosa layer and oriented in the direction of the longitudinal or circular muscle to record isometric contractile activity. Strips (approximately 15-mm long), consisting of the longitudinal muscle with the myenteric plexus attached were dissected from ileal intestinal segments. The taenia coli muscle strips used were 4- to 5-mm long. In one of the experimental series, whole segment preparations (approximately 25-mm long) were dissected from the terminal ileum and mounted vertically for recording of contractile activity in the direction of the longitudinal muscle layer. Each preparation was allowed to equilibrate at zero tension for 20 min, followed by consecutive loading with 0.20-g increments until a level of optimal resting tension (To) was achieved. Resting tension was considered optimal when the contractile response to carbachol (1 µM) or 5-hydroxytryptamine (5-HT, 10 µM) ceased to increase with loading. All experiments were performed at To and isometric contractions were monitored via isometric transducers (Radnoti Glass Technology Inc., Monrovia, CA) and recorded on a Grass-7 polygraph (Grass Instrument Co., Quincy, MA).
Electrical Field Stimulation. Neurally mediated responses were elicited by electrical field stimulation (EFS) applied via pairs of platinum wire electrodes placed parallel to the muscle strips. Submaximal contractile responses, allowing the measurement of both reduction and potentiation of the neurally mediated contractions, were considered an appropriate model to study the effects of TAK-637. Electrical stimuli were generated by a Grass-88 stimulator (Grass Instrument Co.). Contractile responses of isolated longitudinal colonic muscles were evoked by rectangular pulses (0.5 ms pulse duration) applied in 5-s train at 5- to 10-min intervals. Pulse frequencies within the train were increased from 1 to 16 Hz to induce frequency-dependent responses. An electromotor force of 50 V was found to induce submaximal (80-95% of carbachol maximum) contraction of the longitudinal colonic muscle to stimulation frequency of 16 Hz. Consequently, a constant voltage of 50 V was used with all frequencies of stimulation. Identical parameters of stimulation were used to elicit nonadrenergic, noncholinergic (NANC) responses in colonic longitudinal muscles treated with atropine (1 µM) and guanethidine (10 µM). Cholinergic neurally mediated responses were elicited in ileal longitudinal muscle-myenteric plexus strips by single-pulse stimulation (0.5 ms pulse duration) applied at a frequency of 0.1 Hz. Submaximal twitch contractions of the longitudinal muscle were obtained by increasing the voltage by 5-V increments (starting at 10 V) until a maximal response was obtained. The voltage was then reduced by 5 V. Under these conditions, the evoked contractions were equal to 70 to 80% of the maximum.
Experimental Design.
Intestinal muscle preparations that
functionally express tachykinin NK1,
NK2, or NK3 receptors were
used to characterize antagonist potency and receptor specificity of
TAK-637 effects in the gastrointestinal tract. To achieve equilibrium
with NK1 receptors, each concentration of TAK-637
was added into the bath solution 30 min prior to construction of an
agonist concentration-response curve or EFS. The effects of TAK-637 on
concentration-response curves induced by selective tachykinin receptor
agonists were investigated in the following preparations: 1)
longitudinal colonic muscle showing NK1
receptor-mediated contractions to
[Sar9,Met(O2)11]-SP
or GR 73632; 2) circular colonic muscle showing
NK2 receptor-mediated contractions to GR 64349 (Maggi et al., 1994
); and 3) the taenia coli muscle showing
NK3 receptor-mediated contractions to senktide (Croci et al., 1995
). The blockade of nerve conduction by tetrodotoxin (TTX, 1 µM) was used to distinguish between a neuronal and
non-neuronal (smooth muscle) site of action of TAK-637. The effects of
TAK-637 on neurally mediated responses were evaluated in the
longitudinal muscle of the colon. The action of TAK-637 at cholinergic
neuromuscular junctions was studied using electrically induced twitch
contractions in longitudinal muscle-myenteric plexus strips isolated
from the guinea pig ileum. Finally, the effects of TAK-637 were studied in isolated segments of terminal ileum, where capsaicin (10 µM) was
applied to stimulate primary afferents and induce local efferent motor
responses (Bartho et al., 1982
, 1999
).
Data Analysis and Statistics.
Contractions were measured in
millinewtons and normalized for the cross-sectional area of the muscle
strip (millimeters squared). The cross-sectional area was calculated as
a function of the length of the muscle at To (millimeters), the wet
weight (milligrams), and smooth muscle density of 1.05 mg/mm3 (Gordon and Siegman, 1971
). In the
experiments designed to study the action of TAK-637 on neurally
mediated or capsaicin-induced contractions of isolated intestinal
segments, responses were expressed as percentage of the contraction
induced by carbachol (1 µM) applied to each preparation at the
beginning of the experiment. Differences between the maximal effect of
the agonist in the presence and absence of TAK-637 were tested using a
paired or unpaired t test, after confirming that the data
showed normal distribution with equal variances. Concentration-response
curves were constructed in the absence and presence of increasing
concentrations of TAK-637 and analyzed fitting the data to a sigmoid
dose-response curve by a nonlinear regression using the PRIZM program
from GraphPad Software, Inc. (San Diego, CA). The obtained dose ratios
(DRs) were further subjected to Schild analysis. An equilibrium
dissociation constant (Kb) for TAK-637
was obtained as the antilog of pA2
derived from the linear regression of mean values of the log (DR
1)
plotted against the negative log of TAK-637 concentration. To
investigate whether the effect of TAK-637 is neurally mediated,
Kb values were estimated in control or
TTX-pretreated colonic longitudinal muscles using
concentration-response curves to GR 73632 obtained in the absence and
presence of a single concentration of 100 nM TAK-637.
Kb values based on a single shift of
the agonist dose-response curve were calculated by the equation:
|
Solutions and Drugs.
The modified Krebs-bicarbonate buffer
used in the experiments was of the following composition: 120 mM NaCl,
6 mM KCl, 1.2 mM MgCl2, 1.2 mM
NaH2PO4, 2.5 mM
CaCl2, 14.4 mM NaHCO3, and
11.5 mM glucose. The following substances were purchased from Sigma-RBI (Natick, MA):
[Sar9,Met(O2)11]-substance
P, GR 73632, GR 64349, succinyl-[Asp6,N-Me-Phe8]-fragment 6-11(senktide), and MEN-10376. The putative
NK1 receptor antagonist TAK-637 was kindly
provided by Takeda Chemical Company (Osaka, Japan). The peptide
compounds
[Sar9,Met(O2)11]-SP,
GR 73632, GR 64349, and senktide were dissolved in distilled water, and
stock solutions of 1 mM concentration were stored at
20°C. Working
dilutions were prepared fresh for each experiment. TAK-637 and
MEN-10376 were dissolved in dimethyl sulfoxide (DMSO). The final
concentration of DMSO in the bathing solution did not exceed 0.01% and
had no significant effect on muscle contractions.
| |
Results |
|---|
|
|
|---|
Antagonist Potency of TAK-637 against NK1
Receptor-Mediated Contractions.
Longitudinal muscles isolated from
the guinea pig colon were studied in the presence of atropine (1 µM)
to prevent cholinergically mediated contractions. Under the influence
of atropine, the preparations would not respond to carbachol;
therefore, the optimal tension was adjusted by examining the
contractile response induced by 5-HT (10 µM). Under these
experimental conditions, the selective NK1
receptor agonists
[Sar9,Met(O2)11]-SP
or GR 73632 was added cumulatively at concentrations increasing from
0.1 nM to 1 µM to induce concentration-dependent contractions. The
contractile responses showed no tachyphylaxis and were reproducible after washing. However, it was interesting to discover that GR 73632-induced maximal contraction was lower in amplitude compared with
[Sar9,Met(O2)11]-SP.
Complete concentration-response curves for both
[Sar9,Met(O2)11]-SP
and GR 73632 were obtained in preparations pretreated for 30 min with
the vehicle (DMSO) or increasing concentrations of TAK-637 (1-100 nM).
Application of DMSO (0.1% v/v) had no significant effect on
spontaneous contractile activity or the concentration-effect curves for
[Sar9,Met(O2)11]-SP
or GR 73632. TAK-637 showed no changes of spontaneous activity and did
not significantly reduce the maximal responses to
[Sar9,Met(O2)11]-SP
or GR 73632 (Table 1). Nonetheless,
TAK-637 induced a concentration-dependent shift of the dose-response
curves to higher concentrations of [Sar9,Met(O2)11]-SP
(Fig. 1a) and GR 73632 (Fig.
2a). The EC50
values obtained in the absence and presence of TAK-637 are given in
Table 1. Schild plot of the rightward shifts of the
concentration-effect curves to
[Sar9,Met(O2)11]-SP
yielded a straight line (linear coefficient 0.97) with a slope of
1.09 ± 0.14 (95% CL, 0.81-1.23) and a
Kb value of 4.7 nM (Fig. 1b). The
Schild analysis of the effect of TAK-637 on GR 73632 responses yielded
a straight line (linear coefficient 0.99) with a slope of 0.80 ± 0.08 (95% CL, 0.62-1.12) and a Kb value of 1.8 nM (Fig. 2b).
|
|
|
|
Receptor Specificity of Effects of TAK-637.
To establish
whether TAK-637 is a selective NK1 receptor
antagonist, concentration-response curves for the contractile responses induced by selective activation of NK2 or
NK3 receptors were studied in the absence and
presence of TAK-637. In colonic circular muscle that functionally
expresses NK2 receptors, TAK-637 (100 nM) had no
significant effect on the concentration-response curve for the
contractile effect of a selective NK2 receptor
agonist, GR 64349 (0.1 nM-1 µM). In contrast, the selective
antagonist of NK2 receptors, MEN-10376
(100 nM), caused a parallel shift of the concentration-response curve
to higher concentrations with a DR of 2.6 (Fig.
4a). The taenia coli preparation
expresses NK3 receptors that are activated by the
selective NK3 receptor agonist senktide, causing
a contractile response. Pretreatment of the taenia coli with TAK-637
(100 nM) had no significant effect on the concentration-effect curves
obtained for senktide (0.1 nM-1 µM) (Fig. 4b).
|
Effects of TAK-637 on Neurally Mediated Responses.
In the
longitudinal muscle of the colon, EFS (0.5 ms pulse duration, 1-16 Hz
pulse frequency, 5-s train duration) induced frequency-dependent
responses, which were abolished by TTX (1 µM). Responses to stimulus
frequencies of 1 to 4 Hz showed an initial inhibitory component
developing during stimulation, which was followed by an "off"
contractile response. High frequencies (8-16 Hz) of stimulation
induced only contractile responses. Since the inhibitory component
depends on the level of resting tension, which was relatively low
(0.2-0.5 g/mm2) in colonic longitudinal muscle,
the effect of TAK-637 was investigated only against the contractile
response. TAK-637 (100 nM) did not alter the contractile responses to
all frequencies of stimulation (Fig. 5a).
In a separate set of experiments, colonic muscles were pretreated with
atropine (1 µM) and guanethidine (10 µM), and EFS was applied to
induce NANC responses. NANC contractile responses were of lower
amplitude, compared with untreated controls, and increased with the
increase in stimulus frequency. TAK-637 (100 nM) did not significantly
change the NANC contractions, except for responses to the highest
stimulus frequencies (8-16 Hz), which showed a modest but significant
(p < 0.05) reduction by TAK-637 (Fig. 5b).
|
Effects of TAK-637 on Capsaicin-Induced Contractions.
Capsaicin is a sensory neuron stimulant that releases SP and depletes
primary sensory afferent neurons of the small nonmyelinated type
associated with pain sensation. In isolated segments of terminal ileum,
the initial application of capsaicin (10 µM) induced a contractile
response that involves the effect of endogenous tachykinins. To avoid
the effect of SP depletion, a single application of capsaicin was
tested in each preparation. In untreated control preparations, the
contractile response to capsaicin was 68 ± 7% of carbachol contraction, whereas pretreatment with TAK-637 (100 nM) completely prevented the development of capsaicin-induced contractions (Fig. 6). In contrast, the response to
capsaicin was significantly (p < 0.001) reduced, but
not abolished by atropine (1 µM). The development of
capsaicin-induced contraction was completely blocked by pretreatment with TTX (1 µM).
|
| |
Discussion |
|---|
|
|
|---|
Our results demonstrate that TAK-637 has peripheral activity
acting as a selective and competitive antagonist of
NK1 receptors in the gastrointestinal tract. In
the isolated longitudinal muscle of the guinea pig colon, TAK-637
showed high antagonist affinity against contractions induced by
[Sar9,Met(O2)11]-SP
or GR 73632 with Kb values in the
nanomolar range. However, as indicated by the
Kb values (4.7 nM versus 1.8 nM), the antagonist affinity of TAK-637 was 2.6 times higher when
calculated against the contractile responses to GR 73632 compared with
[Sar9,Met(O2)11]-SP
contractile responses. Such a difference in the affinity of a single
antagonist is not uncommon when comparing the effects of an
NK1 receptor antagonist against C-terminal
truncated (GR 73632) and full-length
([Sar9,Met(O2)11]-SP)
analogs of SP (Patacchini et al., 1995
; Jenkinson et al., 1999
). In
addition, although GR 73632 and
[Sar9,Met(O2)11]-SP
had similar potency (EC50 values were 12.1 and
17.0 nM, respectively) in the longitudinal colonic muscle, the
amplitude of the maximal response to GR 73632 was about 2 times higher
than the response to
[Sar9,Met(O2)11]-SP.
Taken together, the results suggest that TAK-637, similar to other
nonpeptide antagonists (Longmore et al., 1994
; Zeng and Burcher, 1994
;
Patacchini et al., 1995
), may show variable affinity for a single
NK1 receptor population, depending on the agonist with which it competes. In the broader context of drug-receptor interaction, these discrepancies suggest that GR 73632 and
[Sar9,Met(O2)11]-SP
bind differentially to the NK1 receptor in the
nanomolar range.
In addition to inducing a direct contractile effect, tachykinins have
been shown to regulate intestinal activity via neuronal NK2 (Zagorodnyuk et al., 1995
),
NK3 (Maggi et al., 1993a
), and NK1 (Johnson et al., 1998
; Lecci et al., 1999
)
receptors. In the current study, experiments were designed to
differentiate between the neuronally mediated and direct effects of
TAK-637. The DR and Kb calculated for
a single shift of the dose-response curves to GR 73632 produced by
TAK-637 (100 nM) in colonic longitudinal muscles pretreated with TTX
were similar to the respective values obtained in untreated
preparations. These findings imply that in the colonic longitudinal
muscle, TAK-637 antagonizes the effect of a non-neuronal
NK1 receptor. Moreover, we have demonstrated that
TAK-637 is a selective antagonist interacting with
NK1 but not NK2 or
NK3 receptors. TAK-637 was ineffective against
the contractile responses of circular colonic muscle to a
NK2 receptor agonist GR 64349 or against the
NK3 receptor-mediated contractions of the taenia
coli induced by senktide. In summary, TAK-637 was defined as a
competitive antagonist interacting selectively with smooth muscle
NK1 receptors causing contraction in the guinea pig colon.
Electrical field stimulation was used to further characterize the peripheral action of TAK-637 in the gastrointestinal tract by investigating its effect on neuromuscular motor responses. However, despite the fact that TAK-637 antagonizes the effect of exogenous SP in the longitudinal muscle of the colon, a significant inhibitory effect of TAK-637 was found only against NANC contractile responses induced by high frequencies of EFS. Also, the cholinergic twitch contractions induced by EFS in the longitudinal muscle-myenteric plexus strips were unaffected by TAK-637. The discrepancy between the effect of TAK-637 on responses induced by exogenous SP and the lack of a complete inhibitory effect on motor neurally mediated responses could be explained by the method of intramural nerve stimulation. Responses elicited by EFS are the net effect of stimulation of all intramural nerve terminals sensitive to the applied stimulus, and the muscle response reflects exclusively the immediate release of neurotransmitters at the neuroeffector, i.e., neuromuscular junction. Thus, the negative results obtained with TAK-637 suggest that TAK-637 has no effect on the motor neurotransmission at cholinergic and NANC neuromuscular junctions, at which SP is not an immediate neurotransmitter. A small portion of the contraction in response to NANC stimulation at higher frequency was blocked by TAK-637, indicating that TAK-637 may selectively inhibit the component of neuromuscular motor responses that is mediated by NK1 receptors.
A capsaicin-stimulated component of intestinal sensory-motor reflexes
is maintained in the isolated intestine and was used as a model to
study the effects of TAK-637. In the guinea pig ileum, capsaicin
stimulates primary afferent nerve terminals, which in turn activate
cholinergic (and to a smaller extent noncholinergic) motor neurons,
causing a net contractile response (Bartho et al., 1982
). Since the
capsaicin-induced contraction was followed by a rapid desensitization
of capsaicin-sensitive sensory neurons, a single response was induced
in either control or TAK-637-pretreated segments of terminal ileum. The
striking lack of response in TAK-637-treated preparations compared with
the presence of contractile response in vehicle-treated control
preparations clearly indicated that TAK-637 acts as an inhibitor of a
sensory-motor response in the ileum, which requires an intact
NK1 receptor mediated pathway. However, the
source of receptive input to the capsaicin-sensitive fibers, i.e., the
functional role of the reflex(es) that could be modulated by TAK-637,
requires further investigation. In addition, we found that cholinergic
motor neurons blocked by atropine are responsible for a major portion
of the capsaicin-induced contractile response, since the
capsaicin-induced contraction was reduced by approximately 80% in the
presence of atropine. A small portion (approximately 20%) of the
contractile responses to capsaicin, which was also inhibited by
TAK-637, is due to the effect of a noncholinergic motor transmitter(s)
released simultaneously with acetylcholine. The nature of the
excitatory noncholinergic response was not identified in the present
experiments. In contrast to a recent finding by Bartho et al. (1999)
,
we did not find a "nontachykininergic" component of the
capsaicin-induced excitatory response of the small intestine. The
ability of TAK-637 to inhibit capsaicin-induced response supports the
suggestion that NK1 receptor antagonists have a
therapeutic potential to inhibit effects mediated by enteric neurons
and to block local sensory responses at the periphery. These effects of
TAK-637 may be of particular benefit in the treatment of functional
gastrointestinal disorders.
| |
Acknowledgments |
|---|
We thank Karl Tyler of the Oklahoma Foundation for Digestive Research Basic Science Laboratories for excellent technical assistance with the experiments.
| |
Footnotes |
|---|
Accepted for publication November 16, 2001.
Received for publication October 2, 2001.
Supported by a grant from TAP Pharmaceutical Products Inc., Lake Forest, IL.
The results were presented at the annual meeting of the American Gastroenterological Association at Atlanta, GA, May 20-23, 2001.
Address correspondence to: Dr. Beverley Greenwood-Van Meerveld, Veterans Affairs Medical Center, Research Administration Room 151, 921 N.E. 13th Street, Oklahoma City, OK 73104. E-mail: Beverley-Greenwood{at}ouhsc.edu .
| |
Abbreviations |
|---|
SP, substance P;
To, optimal resting tension;
TTX, tetrodotoxin;
EFS, electrical field stimulation;
NANC, nonadrenergic, noncholinergic;
DMSO, dimethyl sulfoxide;
DR, dose
ratio;
TAK-637, (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g]
[1,7]naphthyridine-6,13-dione;
GR 64349, Lys-Asp-Ser-Phe-Val-Gly-R-
-lactam-Leu-Met-NH2;
GR 73632, H2N-(CH2)4-CO-Phe-Phe-Pro-NMe-Leu-Met-NH2;
MEN-10376, H-Asp-Tyr-D-Trp-Val-D-Trp-D-Trp-Lys-NH2;
CL, confidence limit.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. N. K. Sarma, K. Banwait, A. Basak, A. J. DiMarino, and S. Rattan Inhibitory Effect of beta 3-Adrenoceptor Agonist in Lower Esophageal Sphincter Smooth Muscle: In Vitro Studies J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 48 - 55. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||